Trastuzumab deruxtecan,ado-trastuzumab emtansine
Daiichi Sankyo,AstraZeneca,roche
['confirm,(-confirma),(-confirme)', 't-dxd', 'mbc', 'destiny,breast,2', 'destiny,breast,3', 'breast', 'trastuzumab deruxtecan']
new data from #esmo22 positive pfs findings from subgroup analysis of destiny-breast03, a phase iii trial, confirm superiority of trastuzumab deruxtecan (t-dxd) to trastuzumab emtansine (t-dm1) in treating breast cancer pts with her2+ mbc. 